CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 317 enrolled
Drug / intervention
CTP-543 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04784533
NCT04784533Phase 2Completed
CompareCT.gov

A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Concert Pharmaceuticals·interventional·Posted Mar 5, 2021·Updated Oct 9, 2024

In Brief

A Phase 2 clinical trial evaluating CTP-543 and Placebo for Alopecia Areata. Completed, enrolled 317 participants across 39 sites.

Detailed Summary

This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedMar 5, 2021
Enrollment StartFeb 26, 2021
Primary CompletionMay 16, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.3 years ago

Interventions

CTP-543drug

Oral dosing

Placebodrug

Oral dosing